Abbott presented new late‑breaking clinical data at the Heart Rhythm Society meeting in Chicago, focusing on its pulsed field ablation (PFA) and conduction system pacing (CSP) portfolios.
The presentation highlighted six‑month results from the FlexPulse IDE study, which evaluated the TactiFlex Duo Ablation Catheter, Sensor‑Enabled, and demonstrated positive patient outcomes that confirm the safety and efficacy profile seen in the CE Mark study, supporting the U.S. FDA approval pathway for the TactiFlex Duo.
Volt data were also presented, showing freedom from atrial fibrillation recurrence when the posterior wall was treated in addition to standard ablation, underscoring the system’s potential to address complex AF cases.
Early feasibility results from the ASCEND CSP IDE trial were shared for the investigational UltiSynq CSP ICD lead, and a first‑in‑human study of the AVEIR CSP leadless pacemaker system was also presented, illustrating Abbott’s progress across the CSP spectrum.
These milestones reinforce Abbott’s strategy to capture growing PFA and CSP markets, strengthen its competitive position, and lay the groundwork for future regulatory approvals and market expansion, making the event material for investors and stakeholders.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.